Grossman Adam S 4

What Happened

• Adam S. Grossman, President, CEO and a director of ADMA Biologics (ADMA), exercised options to acquire 15,000 shares at $5.40 (cost $81,000) and on the same day sold 21,000 shares in open-market transactions at $15.16, producing total sale proceeds of $318,360 (15,000 shares for $227,400 and 6,000 shares for $90,960). The filing also reports a derivative disposition of 15,000 shares reported at $0.00 (related to option/derivative settlement).

Key Details

• Transaction date: 2026-03-16. Sale price: $15.16 per share. Exercise price paid for acquired shares: $5.40 per share.
• Total proceeds from sales: $318,360. Cash paid to exercise: $81,000 for 15,000 shares.
• Reported plan: Transactions were effected under a Rule 10b5‑1 trading plan established Nov 14, 2025 (footnote F1).
• Beneficial ownership disclosed (per filing footnotes): 1,218,943 shares directly owned by Grossman, plus unvested RSUs totaling 893,834 (282,529 + 189,017 + 278,864 + 143,424) and outstanding option coverage (option granted Feb 26, 2024 with 217,737 shares vesting first-year; full grant equals ~870,948 underlying shares). Some shares are held through entities Areth, LLC and Hariden, LLC (Grossman has control/manager roles).
• Filing timeliness: Form filed 2026-03-17 reporting 2026-03-16 transactions — no late filing indicated in the record.

Context

• This is a common pattern where an insider exercises options and sells shares the same day. The combination of an exercise (derivative conversion) and immediate sale is often a sell-to-cover or cashless-style transaction; here it was executed under a pre-established 10b5‑1 plan.
• Sales do not necessarily signal a change in sentiment; purchases are typically more informative about bullishness. This filing is factual disclosure of insider activity required by SEC rules.